| Description | BMS-929075 is an orally active HCV NS5B replicase (HCV NS5B replicase) palm site variant inhibitor with potency, high oral bioavailability and pharmacokinetic parameters.BMS-929075 shows cytotoxicity. |
| In vitro | BMS-929075 (0-60 µM) 对Huh-7、HepG2和原代人类肝细胞表现出细胞毒性，其半数细胞抑制浓度（CC50）值分别为60、>12.5和>50 µM。[1] |
| In vivo | BMS-929075（静脉给药2 mg/kg；口服给药6 mg/kg）在大鼠中显示了良好的药代动力学参数，口服生物利用度为48%。[1] |
| Target activity | Huh-7 cells:60 µM(CC50), HepG2 cells:>12.5 µM(CC50) |
| Synonyms | BMS 929075, BMS929075 |
| molecular weight | 538.54 |
| Molecular formula | C31H24F2N4O3 |
| CAS | 1217338-97-0 |
| Storage | |Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 27.5 mg/mL (51.06 mM) |
| References | 1. Yeung KS, et al. Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem. 2017;60(10):4369-4385. |